HIMS Stock Drops After FDA Questions Peptide Safety

• Hims and Hers stock slipped overnight after FDA staff raised safety concerns about the company’s popular peptide products.
• The regulatory scrutiny has created uncertainty around one of the company’s key revenue drivers.
• Despite the overnight decline, at least one analyst maintains confidence that this setback is not the end of the story for the telehealth company.
• The FDA’s questions highlight ongoing regulatory challenges in the rapidly growing peptide supplement market.

AI-generated briefing — triage, not the story; every claim links out to the coverage below.